My Email Letter to Drs. Fauci, Birx, Redfield and Adams
​
​
Dear Drs. Fauci, Birx, Redfield and Adams,
Would you be kind enough to explain how a statement can be made that Remdesivir "block(ed) the (corona) virus" when the data I find shows no reduction in virus shedding between placebo and Remdesivir?
Virus shedding can only occur with the presence of virus. Continued shedding means continued virus, which is the result of continued replication - not the "blocking" of it.
​
​
​
​
I am also interested in knowing why there was a change in the primary outcomes - viz. removing death and ventilator status a mere 8 days before the WH Press Conference last week - given that both Death and Ventilator Status are significant in CoVid-19 patients.
The ventilator status - i.e. patients being on a ventilator - appearing to be a significant reason why the placebo group appears to have been hospitalized for a few more days.
It is well known to any one of us (physicians, nurses, respiratory therapist, etc.) who has taken care of critically ill patients, that adding ventilator time to a hospital stay will increase your length of stay in the hospital - independent of any other treatment you receive.
Why were these changes made on April 16th? Only 8-days before Dr. Fauci said during the WH press conference that he was notified of the outcomes on Friday, April 24th? [You will need your computer to see the following outcomes text.]
​
​
​
I have major concerns when the FDA clears drugs for use, particularly in less than a week. I saw posted today that the FDA has cleared Remdesivir for Emergency Use (EU) in CoVid-19 patients.
According to Forbes, the FDA cleared 59 new drugs in 2018. While I am aware of no drugs ever being refused by the FDA, there have been
234 recalled since 5 October 2017 [Fleming, et al FDA Drug Recalls Epidemic. Response to: Weight loss pill praised as "holy grail" is withdrawn from US market over cancer link. BMJ 2020;368:m705].
That's more drugs recalled than approved during that time period!
​
I also have major concerns with the FDA clearing drugs that are perhaps being misrepresented.
As noted in the BMJ paper, I have prior experience and evidence of this, and I think it is fair to say that my questions raise significant scientific concerns regarding the validity of clearing Remdesivir for EU or as a new "standard of care" for CoVid-19 patients; given the lack of scientific proof that Remdesivir either saved lives or reduced admission time.
I look forward to receiving a logical scientific answer to these questions.
Respectfully,
Dr. Fleming
​
​
